therapies work in only a subset of patients. Too often, averaging the effects of a drug across all patients with a given cancer drowns out the small signal of a subpopulation for which there is a clinical benefit.
Two trials described at last week's annual meeting of the American Association for Can cer Research -a breastcancer study called ISPY 2 and a lungcancer trial codenamed BATTLE -address these issues by allowing researchers to analyse data in the middle of a trial. From this, they can determine which patients are responding to a given drug, and whether biomarkers such as specific mutations are linked to that response. The trial is then restructured, midcourse, to treat patients with the drug that best suits their specific biomark ers. ISPY 2 is also designed for testing to stop if it becomes clear that the drug is not helping, a general ethical benefit to the approach.
In addition to being faster, and therefore cheaper, than traditional approaches, the strat egy should make trials more sensitive to small subpopulations of drugresponsive patients, says Laura Esserman, a surgeon at the University of California, San Francisco, and a lead investigator of ISPY 2. "We are really hoping to drive down the cost of clinical trials 50fold, " she says. "Oth erwise I don't think drug companies are going to be interested in taking the risk of developing a drug for these small numbers of patients. "
The concept of adaptive clinical trials dates back to the 1970s, although it is a route that few investigators have followed given the tradi tional emphasis on adhering to proven trial designs. Krams also notes that some inves tigators use the term 'adaptive' as an excuse to get away with doing shorter trials in fewer patients. "Unfortunately there are cowboys out there who abuse the term 'adaptive design' and use it as a tool to cut corners, " he says.
Some regulators -including the FDAhave also expressed concerns that even legitimate adaptive trials can compromise an experiment's integrity because of the require ment that data be unblinded and analysed mid trial. Changing the course of a trial midstream could allow investigators and participants to infer how the therapy is performing, possibly colouring their perception of the drug's effi cacy and introducing bias. But Seymour says that there are ways to construct a trial to mini mize this risk, and an independent statistician can be included on datamonitoring boards to prevent undue influence on data analysis by trial sponsors.
Ultimately, Pocock says, some of these details will have to be worked out as researchers gain more experience with adaptive trials. "We're all on a learning curve together, " he says.
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Flexible approach allows cancer researchers to change course mid-trial according to patient response. 
Clinical drug tests adapted for speed
